Viatris licenses Idorsia’s PhIII drugs selatogrel and cenerimod with $350M upfront

Viatris has inked a deal with Idorsia for a pair of late-stage drug candidates in a move that may reflect Viatris’ efforts to build its product development muscle.

The development and commercialization partnership is based on two Phase III assets: P2Y12 inhibitor selatogrel for acute myocardial infarction and S1P1 receptor…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks